Mucosal immunization with the lung Lactobacillus -derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P . aeruginosa infection
Haochi Zhang,Shouxin Sheng,Chunhe Li,Xuemei Bao,Lixia Zhao,Jian Chen,Pingyuan Guan,Xiaoyan Li,Na Pan,Yanchen Liang,Xueqi Wang,Jingmin Sun,Xiao Wang
DOI: https://doi.org/10.1371/journal.ppat.1012696
IF: 7.464
2024-11-24
PLoS Pathogens
Abstract:Respiratory infections caused by Pseudomonas aeruginosa are a major health problem globally. Current treatment for P . aeruginosa infections relies solely on antibiotics, but the rise of antibiotic-resistant strains necessitates an urgent need for a protective vaccine. Traditional parenteral vaccines, despite employing potent adjuvants aimed at serotype-dependent immunity, often fail to elicit the desired mucosal immune response. Thus, developing vaccines that target both localized mucosal and systemic immune responses represents a promising direction for future research on P . aeruginosa vaccination. In this study, we explored EPS301, the exopolysaccharide derived from the lung microbiota strain Lactobacillus plantarum WXD301, which exhibits excellent self-assembly properties, enabling the formation of homogeneous nanoparticles when encapsulating recombinant PcrV of P . aeruginosa , designated as EPS301@rPcrV. Notably, the EPS301 vector effectively enhanced antigen adhesion to the nasal and pulmonary mucosal tissues and prolonged antigen retention. Moreover, EPS301@rPcrV provided effective and sustained protection against P . aeruginosa pneumonia, surpassing the durability achieved with the "gold standard" cholera toxin adjuvant. The EPS301-adjuvanted vaccine formulation elicited robust mucosal IgA and Th17/γδ17 T cell responses, which exceeded those induced by the CTB-adjuvanted vaccination and were sustained for over 112 days. Additionally, Th 17 and γδ 17 resident memory T cells induced by EPS301@rPcrV were crucial for protection against P . aeruginosa challenge. Intriguingly, IL-17A knockout mice exhibited lower survival rates, impaired bacterial clearance ability, and exacerbated lung tissue damage upon EPS301 adjuvanted vaccination against P . aeruginosa -induced pneumonia, indicating an IL-17A-dependent protective mechanism. In conclusion, our findings provided direct evidence that EPS301@rPcrV mucosal vaccine is a promising candidate for future clinical application against P . aeruginosa -induced pulmonary infection. Antibiotics currently dominate P . aeruginosa treatment, but rising resistance demands a protective vaccine. Yet, traditional injectable vaccines, even with potent adjuvants targeting serotype immunity, often fall short in inducing the crucial mucosal immune response. Mucosal vaccines excel at inducing antigen-specific protective immune responses at the mucosal barrier, while simultaneously stimulating systemic humoral and cell-mediated immune responses throughout the body. Leveraging its exceptional self-assembly properties, EPS301 has emerged as a promising nasal mucosal adjuvant for vaccines, providing effective and sustained protection against P . aeruginosa -induced pneumonia. While EPS301-adjuvanted vaccination elicited robust lung IgA and serum IgG responses, humoral immunity alone did not confer significant protection. Notably, the protective effect significantly diminished in IL-17A knockout mice, but not IFN-γ knockout mice, suggesting a crucial role for IL-17A in EPS301-mediated immunity. Additionally, intranasal co-administration of EPS301 with rPcrV antigen induced strong lung Th17/γδ17 resident memory T cells, which effectively protected against P . aeruginosa . Our findings highlight EPS301 as a promising mucosal adjuvant for developing intranasal vaccines against P . aeruginosa pneumonia.
microbiology,virology,parasitology